Optimization of protein therapies by polymer-conjugation as an effective DDS.
Due to recent advances in disease proteomics, many disease-related proteins have been found. It is expected that there will be therapeutically useful proteins among them. However, it is clinically difficult to use most proteins as effective and safe drugs because of their very low stability and pleiotropic actions in vivo. To promote disease proteomic based drug development for protein therapies, we have attempted to develop an optimal polymer-conjugation system for improving the therapeutic potency of proteins. In this review, we introduce this innovative protein-drug system.
Shibata
Hiroko
H
Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
Nakagawa
Shinsaku
S
Tsutsumi
Yasuo
Y
D004337:Drug Carriers / Q000138:chemical synthesis / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods*; D004353:Drug Evaluation, Preclinical; D004358:Drug Therapy / Q000379:methods*; D015850:Interleukin-6 / Q000737:chemistry; D008954:Models, Biological; D011092:Polyethylene Glycols / Q000737:chemistry; D011108:Polymers / Q000138:chemical synthesis* / Q000737:chemistry*; D011145:Polyvinyls / Q000737:chemistry; D011506:Proteins / Q000008:administration & dosage* / Q000737:chemistry; D011759:Pyrrolidines / Q000737:chemistry; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000737:chemistry
D004337:Drug Carriers; D015850:Interleukin-6; D011108:Polymers; D011145:Polyvinyls; D011506:Proteins; D011759:Pyrrolidines; D014409:Tumor Necrosis Factor-alpha; C505150:poly(N-vinylpyrrolidine); D011092:Polyethylene Glycols